Navigation Links
Accuray Reports Financial Results for First Quarter of Fiscal Year 2014
Date:11/7/2013

SUNNYVALE, Calif., Nov. 7, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the first fiscal quarter ended September 30, 2013.
Results are presented on a GAAP basis, unless otherwise indicated, as the magnitude of purchase accounting amortization was minimal for fiscal year 2013 and is projected to be minimal for fiscal year 2014 and beyond, making GAAP results comparable on a year over year basis and a good measure of the company's performance.

First Quarter and Recent Highlights

  • Continued strong order momentum with gross orders of $63.4 million, an increase of 17% from the first fiscal quarter of 2013.
  • Gross profit margins improve 590 basis points, operating expenses decline 13% and adjusted EBITDA improves $8.1 million, all compared to the prior year first fiscal quarter.
  • Over 100 oral and poster presentations at the 55th annual American Society for Radiation Oncology (ASTRO) meeting reinforcing clinical and quality of life benefits for the CyberKnife® and TomoTherapy® Systems.
  • "We had a strong start to the fiscal year with most elements of our performance being above our expectations, reflecting strong commercial and operational execution.  Orders into backlog are being driven by the actions we have taken to improve our commercial focus and enable growth through improved business processes.  We expect that product revenues will begin to strengthen over the next several quarters as well," said Joshua H. Levine, president and chief executive officer of Accuray.  "Improving gross profit margins along with continued expense control in narrowing our adjusted EBITDA losses puts the business on a strong trajectory to achieve profitability, along with higher revenues."

    "We are enthusiastic about fiscal 2014 and the continued execution improvem
    '/>"/>

    SOURCE Accuray Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
    2. Accuray Announces First CyberKnife System in South America
    3. Accuray Surpasses 600 Installations Globally
    4. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
    5. Omeros Corporation Reports Third Quarter 2013 Financial Results
    6. Global Positron Emission Tomography Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
    7. Global In Vitro Fertilization Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
    8. Global Biophotonics Market & OSS BSS Industry 2012-2016 Reports
    9. China Vanadium Catalyst Market for Sulfuric Acid Production in A New Research Available at MarketReportsChina.com
    10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
    11. Neurocrine Biosciences Reports Third Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
    (Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
    (Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
    (Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
    Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
    ... 1 Eisai Co., Ltd.,(Headquarters: Tokyo, President & ... of North America (Headquarters: New Jersey,the United States, ... in the schedule for submission to the U.S. ... Application (NDA) for E7389 (generic,name: eribulin mesylate) for ...
    ... 1 , - ENDORSE Global Findings Highlight ... VTE Management: Systematically Assess,Patient Risk for VTE and ... multinational study (Epidemiologic International Day for the,Evaluation of ... Acute,Hospital Care Setting) published today in the LANCET(1) ...
    ... CV Therapeutics,Inc. (Nasdaq: CVTX ) today announced that ... community in New York City on Thursday, February 7,2008 ... be webcast live and available for replay on the,company,s ... CV Therapeutics, Inc., headquartered in Palo Alto, California, ...
    Cached Biology Technology:Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application 2Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 2The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 4CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008 2
    (Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
    (Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
    (Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
    Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
    ... our cells migrate: nerve cells make their vital connections, ... organs, immune cells zero in to destroy pathogenic organisms, ... body. Scientists studying these migrations didn't know how cells ... Institute study has identified a fragment of a protein ...
    ... does matters after all. But for flying snakes, smaller ... In the May 15, 2005, issue of the Journal ... and behavior of flying snakes, and found that the ... of wing-like appendages, flying snakes are skilled aerial locomotors," ...
    ... Virginia Tech, has been awarded a Ralph E. Powe Junior ... his research on quorum sensing in bacteria. He is modeling ... by a bacteria colony once it has reached a critical ... to faculty members who are in the first two years ...
    Cached Biology News:New understanding of cell movement may yield ways to brake cancer's spread 2Researchers reveal secrets of flying snakes 2Researchers reveal secrets of flying snakes 3Understanding how bacteria communicate may help scientists prevent disease 2Understanding how bacteria communicate may help scientists prevent disease 3
    B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
    ...
    Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
    Biology Products: